Abstract
Chlorpromazine hydrochloride (CPZ) refers to antipsychotic drugs. CPZ is drug of first choice for the treatment of schizophrenia. However, its impact on the main excitatory neurotransmitter system, glutamatergic, is unclear. This issue is the aim of our study. Experiments carried out on brain slices of the olfactory cortex of rats. We used electrophysiological techniques extracellular recordings in brain slice to investigate CPZ effects on the activity of the glutamatergic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic receptors (AMPAR) and N-methyl-D-aspartic acid type glutamate receptors (NMDAR).
Highlights
Chlorpromazine (CPZ) is on the World Health Organization list of essential medicines remains drug of first choice for the treatment of schizophrenia despite the emergence of other drugs [1,2].Chlorpromazine hydrochloride, the most commonly used form of CPZ in the clinic, refers to a group of antipsychotic drugs
In order to assess the degree of interaction CPZ with AMPAR and N-methyl-D-aspartic acid type glutamate receptors (NMDAR) and the duration its effects on these receptor mechanisms we has been used the test on reversibility of CPZ action during washing
In the present study we investigated the effects of CPZ, a widely used antipsychotic, on the activity of ionotropic glutamatergic receptors, AMPAR and NMDAR
Summary
Chlorpromazine hydrochloride (some synonyms aminazine, largactil, thorazine, etc.), the most commonly used form of CPZ in the clinic, refers to a group of antipsychotic drugs. It is a dimethylamine derivative of phenothiazine, has a chemical formula of C17H20Cl2N2S and molecular weight: 355.321 g/mol. CPZ has strong antiadrenergic and weak peripheral anticholinergic activity. It possesses slight antihistaminic and antiserotoninergic activity [4,5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Brain Disorders and Treatment
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
